Get the app
US › Healthcare

Reviva Pharmaceuticals Holdings Inc. (RVPH)

US · Healthcare · Biotechnology

$0.48-10.26%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-2.45T
EPS
$-0.19
EPS estimate
$-0.41

EPS came in at -0.19 against a street estimate of -0.41 — a beat of 53.7%.

Key statistics

Market cap
$7.0M
Forward P/E
0.0
P/B
0.46
Book value
$1.16
EPS (TTM)
$-1.03
52-week high
$17.20
52-week low
$0.26
50-day MA
$0.50
200-day MA
$2.75
Beta
0.50

Analyst view

Analysts rate Reviva Pharmaceuticals Holdings Inc. a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $17.50.

Shareholding

Insiders
7.73%
Institutions
8.24%

Largest institutional holders

FundStake
Highbridge Capital Management, LLC5.81%
Armistice Capital, LLC4.52%
Vanguard Capital Management, LLC0.90%
Geode Capital Management, LLC0.56%
Renaissance Technologies Corp0.33%
Virtu Financial LLC0.25%
Vanguard Fiduciary Trust Co0.24%
State Street Corp0.15%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Reviva Pharmaceuticals Holdings Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.